Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Shares Jump 8 Percent as Xenogen Unit Pens Target Validation Deal With Schering-Plough

NEW YORK (GenomeWeb News) - Caliper Life Sciences business unit Xenogen Biosciences will collaborate with Schering-Plough Research Institute to validate targets in drug discovery, Xenogen said today.
 
News of the alliance caused shares in Caliper to trade up 8.07 percent, or $.37, at $4.97 mid-afternoon today.
 
Xenogen Biosciences will use its serial phenotyping compression technology to characterize high value targets. The technology relies on a battery of more than 85 pharmacologically validated bioassays.
 
The agreement expands on a previous gene targeting agreement to create standard and conditional gene knockouts.
 
 
Financial details were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.